|2004D-0378|| International Conference on Harmonisation; Draft Guidance on S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals|
|FDA Comment Number :||EC4|
|Submitter :||Mrs. kim salzwedel||Date & Time:||11/17/2005 02:11:28|
|Organization :||Mrs. kim salzwedel|
|Category :||Drug Industry|
| please demand guidance intended to
facilitate the nonclinical assessment of the effects of pharmaceuticals
on ventricular repolarization and proarrhythmic risk is implemented.